The basic rational is that the stabilized form of chemokines that induce Tr1-like cells, among them CXCL12 and CXCL11, could be used for therapy of autoimmunity and GVHD, whereas stabilized CXCL10 would be used for cancer therapy. The gene discussed is CXCL11; the disease is graft versus host disease.